Maze Therapeutics, Inc.
Coloma Jason V (Chief Executive Officer) sold 34,501 indirectly-held shares of Maze Therapeutics, Inc. (MAZE) at an average of $26.73 ($26.71–$27.09, $0.92M total) across 4 trades on 2026-08-03 under a Rule 10b5-1 trading plan.
Maze Therapeutics said Phase 2 HORIZON topline results for MZE829 in APOL1-mediated kidney disease were positive, and its MZE782 program continues toward Phase 2 in PKU and CKD. It also began the Phase 2 ESPRIT trial for partnered S-606001, leading to a $20 million milestone payment from Shionogi. MAZE is a clinical-stage biotech with no FDA-approved AMKD therapies.
Coloma Jason V (Chief Executive Officer) sold 34,501 indirectly-held shares of Maze Therapeutics, Inc. (MAZE) at an average of $29.98 ($29.95–$30.44, $1.03M total) across 3 trades on 2026-07-01 under a Rule 10b5-1 trading plan.
Over the past 7 days, alphai's AI scored 1 news story mentioning MAZE (Maze Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent MAZE coverage spans insider activity, technology and corporate actions.
In the last 30 days, MAZE insiders filed 6 SEC Form 4 transactions — no purchases and 6 sales ($1.1M). The most active reporter was Coloma Jason V, Chief Executive Officer, with 4 filings. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
This is a routine insider sale under a pre-arranged 10b5-1 plan, so it is more a positioning signal than a fundamental catalyst.
Clinical-stage readouts and trial initiation increase near-term probability of further development milestones, supporting risk-on positioning but with typical biotech uncertainty.
Routine 10b5-1 insider selling by the CEO, likely more about planned liquidity than a new negative fundamental signal.
Routine 10b5-1 insider selling provides limited signal, but it can slightly affect near-term sentiment and positioning.
This is corporate governance housekeeping (board/auditor votes) with limited direct fundamental change.
alphai scores every news story that mentions MAZE with an AI model for sentiment and relevance, and aggregates insider trades from Maze Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Coloma Jason V (Chief Executive Officer) sold 34,501 indirectly-held shares of Maze Therapeutics, Inc. (MAZE) at an average of $26.73 ($26.71–$27.09, $0.92M total) across 4 trades on 2026-08-03 under a Rule 10b5-1 trading plan.
1 min readMaze Therapeutics said Phase 2 HORIZON topline results for MZE829 in APOL1-mediated kidney disease were positive, and its MZE782 program continues toward Phase 2 in PKU and CKD. It also began the Phase 2 ESPRIT trial for partnered S-606001, leading to a $20 million milestone payment from Shionogi. MAZE is a clinical-stage biotech with no FDA-approved AMKD therapies.
2 min readColoma Jason V (Chief Executive Officer) sold 34,501 indirectly-held shares of Maze Therapeutics, Inc. (MAZE) at an average of $29.98 ($29.95–$30.44, $1.03M total) across 3 trades on 2026-07-01 under a Rule 10b5-1 trading plan.
2 min readColoma Jason V (Chief Executive Officer) sold 27,858 indirectly-held shares of Maze Therapeutics, Inc. (MAZE) at an average of $26.04 ($26.00–$26.05, $0.73M total) across 3 trades over 2026-06-22 to 2026-06-23 under a Rule 10b5-1 trading plan.
2 min readMaze Therapeutics, Inc. (MAZE) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001842295 0001842295 2026-06-08 2026-06-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2
2 min readColoma Jason V (Chief Executive Officer) sold 553 indirectly-held shares of Maze Therapeutics, Inc. (MAZE) at $26.24 on 2026-06-01 under a Rule 10b5-1 trading plan.
2 min readColoma Jason V (Chief Executive Officer) sold 6,090 indirectly-held shares of Maze Therapeutics, Inc. (MAZE) at $26.20 ($0.16M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
2 min readBernstein Harold (President, R&D & CMO) sold 1,600 shares of Maze Therapeutics, Inc. (MAZE) at $26.36 on 2026-06-01 under a Rule 10b5-1 trading plan.
2 min readBernstein Harold (President, R&D & CMO) sold 13,253 shares of Maze Therapeutics, Inc. (MAZE) at $25.57 ($0.34M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
2 min readColoma Jason V (Chief Executive Officer) sold 4,504 indirectly-held shares of Maze Therapeutics, Inc. (MAZE) at $26.00 ($0.12M total) on 2026-05-22 under a Rule 10b5-1 trading plan.
1 min read
